Phase 4
N=75
Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia
Surgery
Bottom Line
View on ClinicalTrials.gov: NCT03820388 ↗Enrolled (actual)
75
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Blood Pressure — 105; 122; 117.88 mmHg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Propofol 2mg/kg (Drug); Etomidate 0.3 mg/kg (Drug); Propofol 1 mg/kg (Drug); Etomidate 0.15 mg/kg (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, Davis
- Primary completion
- Jul 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Pressure |
105; 122; 117.88 | — |
| PRIMARY Heart Rate |
77; 74; 74 | — |
| SECONDARY Pain at Injection Site |
7; 0; 0 | — |
| SECONDARY Myoclonic Movements |
1; 6; 1 | — |
| SECONDARY Post-operative Nausea and Vomiting |
0; 1; 2 | — |
| SECONDARY Sedation Depth |
30; 38; 38 | — |
| SECONDARY Eyelash Reflex Disappear Time |
31.9; 34.5; 32.4 | — |
| SECONDARY Intubation Time |
92; 95; 93 | — |
Summary
Comparison of Etomidate plus Propofol vs. Propofol or Etomidate alone during induction of anesthesia.
Eligibility Criteria
Inclusion Criteria
- Patients scheduled for elective non-cardiac surgery
- ASA physical status of 2 or 3
- Age equal to or greater than 18 years old
Exclusion Criteria
- Adults unable to provide consent
- Age less than 18 years old
- Pregnant women
- Prisoners
- Difficult airway
- Morbid Obesity
- Preoperative sedation use
- Severe Cardiac, pulmonary and liver disease
- Hypotension and shock
- Emergency surgeries
- Allergy to propofol or etomidate
Data sourced from ClinicalTrials.gov (NCT03820388). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.